ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
Open on Zacks
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

ANI Pharmaceuticals (ANIP) reported $290.78 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 27.6%. EPS of $2.70 for the same period compares to $2.04 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $280.17 million, representing a surprise of +3.79%. The company delivered an EPS surprise of +24.42%, with the consensus EPS estimate being $2.17.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Revenues- Generic pharmaceutical products: $104.46 million versus the four-analyst average estimate of $89.98 million. The reported number represents a year-over-year change of +10.7%. Total Net Revenues- Rare Disease: $160.91 million versus $166.65 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +35.9% change. Net Revenues- Rare Disease and Brands- ILUVIEN and YUTIQ: $22.25 million versus the four-analyst average estimate of $19.42 million. The reported number represents a year-over-year change of +34.1%. Net Revenues- Rare Disease and Brands- Cortrophin Gel: $138.66 million compared to the $147.23 million average estimate based on four analysts. The reported number represents a change of +36.1% year over year. Brand royalties and other revenues: $11.46 million versus $10.22 million estimated by three analysts on average. Net Revenues- Brands: $9.98 million versus the two-analyst average estimate of $11.33 million. The reported number represents a year-over-year change of -6.5%. Total Net Revenues- Generics and Other: $108.43 million versus $93.19 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.9% change. Total Net Revenues- Rare Disease and Brands: $182.35 million versus the two-analyst average estimate of $186.61 million. The reported number represents a year-over-year change of +41.2%.

View all Key Company Metrics for ANI here>>>

Shares of ANI have returned -0.4% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research